AKTS - Aktis Oncology, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$35.00
LOW:
$31.00
MEDIAN:
$33.00
CONSENSUS:
$33.00
UPSIDE:
50.48%
| Metric | 2026 Q1 | 2025 Q4 | 2024 Q4 |
|---|---|---|---|
| Revenue | |||
| Revenue | 3.2 | 1.9 | 0.9 |
| Cost of Revenue | 0.7 | 0 | 0 |
| Gross Profit | 2.6 | 1.9 | 0.9 |
| Operating Expenses | |||
| R&D Expenses | 20.0 | 16.5 | 12.6 |
| SG&A Expenses | 5.2 | 2.5 | 3.9 |
| Other Expenses | 0 | 0.2 | 0.0 |
| Operating Expenses | 25.3 | 19.2 | 16.6 |
| Operating Income | |||
| Operating Income | (22.7) | (17.4) | (15.6) |
| Interest Expense | 0 | 0 | 0 |
| Interest Income | 4.4 | 2.2 | 3.6 |
| Profitability | |||
| EBITDA | (17.7) | (14.4) | (15.2) |
| EBIT | (18.3) | (15.1) | (15.6) |
| Income Before Tax | (18.3) | (15.1) | (12.1) |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (18.3) | (15.1) | (12.1) |
| Per Share Data | |||
| EPS (Basic) | -0.33 | -0.28 | -0.23 |
| EPS (Diluted) | -0.33 | -0.28 | -0.23 |
| Shares Outstanding | 55.3 | 53.4 | 52.5 |
| Metric | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|
| Current Assets | |||||
| Cash & Cash Equivalents | 371.6 | 37.8 | 180.3 | 37.2 | 224.6 |
| Short-Term Investments | 166.9 | 189.0 | 66.0 | 260.0 | 87.8 |
| Net Receivables | 2.2 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.3 | 3.5 | 3.2 | 3.7 | 3.0 |
| Total Current Assets | 543.9 | 230.3 | 249.4 | 300.9 | 315.4 |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 28.1 | 27.2 | 24.3 | 20.9 | 19.4 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.1 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.6 | 7.3 | 5.3 | 4.5 | 2.3 |
| Total Non-Current Assets | 32.9 | 34.6 | 29.6 | 25.3 | 21.7 |
| Total Assets | 576.8 | 264.9 | 279.0 | 326.2 | 337.1 |
| Current Liabilities | |||||
| Account Payables | 1.2 | 1.7 | 2.4 | 1.9 | 0.7 |
| Short-Term Debt | 1.4 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 19.0 | 18.7 | 16.1 | 9.3 | 8.7 |
| Other Current Liabilities | 5.0 | 4.6 | 2.8 | 3.1 | 1.9 |
| Total Current Liabilities | 27.9 | 31.2 | 26.9 | 18.8 | 17.0 |
| Non-Current Liabilities | |||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 333.4 | 333.4 | 333.4 | 333.4 |
| Total Non-Current Liabilities | 42.8 | 379.8 | 384.5 | 395.2 | 396.9 |
| Total Liabilities | 70.7 | 411.0 | 411.4 | 414.0 | 413.9 |
| Stockholders' Equity | |||||
| Common Stock | 0.0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (174.9) | (156.6) | (141.4) | (92.8) | (80.8) |
| Accumulated Other Comprehensive Income | (0.2) | 0.0 | 0.0 | 0.1 | 0.2 |
| Total Stockholders' Equity | 506.1 | (146.1) | (132.4) | (87.8) | (76.8) |
| Total Liabilities & Equity | 576.8 | 264.9 | 279.0 | 326.2 | 337.1 |
| Debt Metrics | |||||
| Total Debt | 11.6 | 11.5 | 11.9 | 12.0 | 12.4 |
| Net Debt | (360.1) | (26.2) | (168.4) | (25.1) | (212.2) |
| Metric | 2026 Q1 | 2025 Q4 | 2024 Q4 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | (18.3) | (15.1) | (12.1) |
| Depreciation & Amortization | 0.7 | 0.7 | 0.4 |
| Stock-Based Compensation | 0 | 1.1 | 1.1 |
| Change in Working Capital | (9.1) | (1.2) | (0.6) |
| Other Non-Cash Items | 2.5 | (0.7) | (1.7) |
| Operating Cash Flow | (24.2) | (15.2) | (12.8) |
| Investing Activities | |||
| Capital Expenditure | (1.9) | (4.2) | (2.2) |
| Acquisitions | 0 | 0 | 0 |
| Purchases of Investments | 0 | (183.1) | (204.9) |
| Sales/Maturities of Investments | 22.4 | 60.8 | 34.2 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | 20.5 | (126.5) | (172.9) |
| Financing Activities | |||
| Net Debt Issuance | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.0) | (1.8) |
| Financing Cash Flow | 337.5 | (0.8) | (1.8) |
| Cash Position | |||
| Net Change in Cash | 333.8 | (142.5) | (187.5) |
| Cash at Beginning | 37.8 | 181.4 | 225.8 |
| Cash at End | 371.6 | 38.9 | 38.3 |
| Free Cash Flow | (26.1) | (19.4) | (15.0) |
| Key Metrics | 2026 Q1 | 2025 Q4 | 2024 Q4 | ||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.2 | 1.9 | 0.9 | ||
| Gross Profit | 2.6 | 1.9 | 0.9 | ||
| Operating Income | (22.7) | (17.4) | (15.6) | ||
| Net Income | (18.3) | (15.1) | (12.1) | ||
| EPS (Diluted) | -0.33 | -0.28 | -0.23 | ||
| Balance Sheet | |||||
| Cash & Equivalents | 371.6 | 37.8 | 180.3 | 37.2 | 224.6 |
| Total Assets | 576.8 | 264.9 | 279.0 | 326.2 | 337.1 |
| Total Debt | 11.6 | 11.5 | 11.9 | 12.0 | 12.4 |
| Stockholders' Equity | 506.1 | (146.1) | (132.4) | (87.8) | (76.8) |
| Cash Flow | |||||
| Operating Cash Flow | (24.2) | (15.2) | (12.8) | ||
| Capital Expenditure | (1.9) | (4.2) | (2.2) | ||
| Free Cash Flow | (26.1) | (19.4) | (15.0) | ||